LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+0.03%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$970M
AUM Growth
+$970M
(-30%)
Cap. Flow
-$201M
Cap. Flow
% of AUM
-20.76%
Top 10 Holdings %
Top 10 Hldgs %
49.08%
Holding
83
New
26
Increased
6
Reduced
23
Closed
17
Top Buys
| 1 |
Ventyx Biosciences
VTYX
|
$36.2M |
| 2 |
Repare Therapeutics
RPTX
|
$35.4M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$22M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$21.7M |
| 5 |
Cytokinetics
CYTK
|
$14.8M |
Top Sells
| 1 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$62.9M |
| 2 |
Kezar Life Sciences
KZR
|
$44.3M |
| 3 |
PMV Pharmaceuticals
PMVP
|
$41.7M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$36.8M |
| 5 |
Nkarta
NKTX
|
$35.5M |
Sector Composition
| 1 | Healthcare | 99.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $62.5M | 6.44% | 2,906,352 -250,629 | -8% | -$5.39M |
|
|
2
Cytokinetics
CYTK
$4.23B
| $60.4M | 6.23% | 1,325,000 +325,000 | +33% | +$14.8M |
|
3
Design Therapeutics
DSGN
$315M
| $59.4M | 6.12% | 2,772,501 | – | – |
|
|
BCYC
4
Bicycle Therapeutics
BCYC
$511M
| $53M | 5.46% | 870,000 -605,000 | -41% | -$36.8M |
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $47.3M | 4.88% | 1,000,000 -450,000 | -31% | -$21.3M |
|
|
DICE
6
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $42.1M | 4.34% | 1,664,251 +504,000 | +43% | +$12.8M |
|
|
KRTX
7
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $39.3M | 4.05% | 300,000 -160,000 | -35% | -$21M |
|
8
Dyne Therapeutics
DYN
$1.92B
| $38.5M | 3.97% | 3,234,392 -385,000 | -11% | -$4.58M |
|
9
Aligos Therapeutics
ALGS
$73.3M
| $36.9M | 3.81% | 3,112,785 +1,150,000 | +59% | +$13.7M |
|
10
IDEAYA Biosciences
IDYA
$2.15B
| $36.6M | 3.78% | 1,550,000 -225,000 | -13% | -$5.32M |
|
|
11
Ventyx Biosciences
VTYX
$171M
| $36.2M | 3.74% | +1,824,280 | New | +$36.2M |
|
|
12
Repare Therapeutics
RPTX
$71.7M
| $35.9M | 3.7% | 1,700,000 +1,680,000 | +8,400% | +$35.4M |
|
13
Olema Pharmaceuticals
OLMA
$375M
| $35M | 3.61% | 3,743,875 | – | – |
|
|
14
Kezar Life Sciences
KZR
$28.9M
| $24.2M | 2.5% | 1,450,000 -2,650,000 | -65% | -$44.3M |
|
|
FMTX
15
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $22.8M | 2.35% | 1,600,000 -515,000 | -24% | -$7.32M |
|
|
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $22M | 2.26% | +750,000 | New | +$22M |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $21.7M | 2.24% | +1,300,000 | New | +$21.7M |
|
18
Athira Pharma
ATHA
$15.3M
| $21.2M | 2.19% | 1,630,744 -225,068 | -12% | -$2.93M |
|
|
VERV
19
DELISTED
Verve Therapeutics
VERV
| $16.3M | 1.69% | 443,265 | – | – |
|
|
ALPN
20
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $15.5M | 1.6% | 1,120,000 +695,000 | +164% | +$9.63M |
|
|
HARP
21
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $14.6M | 1.5% | +1,930,000 | New | +$14.6M |
|
22
Edgewise Therapeutics
EWTX
$1.51B
| $13M | 1.34% | 850,000 +168,188 | +25% | +$2.57M |
|
23
Kymera Therapeutics
KYMR
$2.95B
| $12.7M | 1.31% | +200,000 | New | +$12.7M |
|
24
ESSA Pharma
EPIX
$11.4M
| $12.3M | 1.27% | 865,000 -135,000 | -14% | -$1.92M |
|
25
Fulcrum Therapeutics
FULC
$351M
| $12.1M | 1.25% | +685,000 | New | +$12.1M |
|